Total medical devices industry cross border M&A deals worth $4.64bn were announced globally in Q1 2021, led by Boston Scientific’s $1.07bn asset transaction with Lumenis, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 2.4% over the previous quarter of $4.53bn and a drop of 23.2% when compared with the last four-quarter average, which stood at $6.04bn.
Comparing cross border M&A deals value in different regions of the globe, Europe held the top position, with total announced deals in the period worth $2.37bn. At the country level, the Belgium topped the list in terms of deal value at $1.15bn.
In terms of volumes, Europe emerged as the top region for medical devices industry cross border M&A deals globally, followed by North America and then Asia-Pacific.
The top country in terms of cross border M&A deals activity in Q1 2021 was the US with 17 deals, followed by Canada with seven and Germany with seven.
In 2021, at the end of , cross border M&A deals worth $4.64bn were announced globally in medical devices industry, marking a decrease of 720.3% year on year.
Cross Border M&A deals in medical devices industry in Q1 2021: Top deals
The top five cross border M&A deals in medical devices industry accounted for 77.3% of the overall value during Q1 2021.
The combined value of the top deals stood at $3.59bn, against the overall value of $4.64bn recorded for the quarter.
The top five medical devices industry cross border medical devices deals of Q1 2021 tracked by GlobalData were:
1) Boston Scientific’s $1.07bn asset transaction with Lumenis
2) The $880.85m asset transaction with Novasep Holding by Thermo Fisher Scientific
3) Koninklijke Philips’ $635m acquisition of Capsule Technologies
4) The $591m acquisition of Oxford Immunotec by PerkinElmer
5) Savaria’s acquisition of Handicare Group for $409.7m.
